Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 87 Carcinoma, Non-Small-Cell Lung 78 Multiple Myeloma 72 Prostatic Neoplasms 66 Neoplasms 47 Lymphoma 43 Leukemia, Myeloid, Acute 42 Melanoma 38 Neoplasm Metastasis 37 Lymphoma, Non-Hodgkin 33 Ovarian Neoplasms 32 Lung Neoplasms 32 Squamous Cell Carcinoma of Head and Neck 31 Hematologic Neoplasms 29 Leukemia, Lymphocytic, Chronic, B-Cell 28 Colorectal Neoplasms 26 Triple Negative Breast Neoplasms 23 Hodgkin Disease 23 Precursor Cell Lymphoblastic Leukemia-Lymphoma 21 Myelodysplastic Syndromes 21 Sarcoma 20 Fallopian Tube Neoplasms 20 Pancreatic Neoplasms 19 Carcinoma, Renal Cell 19 Lymphoma, Follicular 17 Leukemia 17 Head and Neck Neoplasms 17 Glioma 17 Urinary Bladder Neoplasms 16 Recurrence 16

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × mCRPC × 90 days × Clear all

NCT03395197 2026-04-22

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡